The Life Science Cluster’s Post

🔔 #BIOMAN4R2 𝙎𝙐𝘾𝘾𝙀𝙎𝙎 𝙎𝙏𝙊𝙍𝙄𝙀𝙎 🇪🇺 ⏩ Check out our #8 Success Story 🏅 Basic Pharma company focusing on the development, production, licensing and registration of pharmaceutical products, based in #Netherlands, was awarded within the 𝙄𝙉𝙉𝙊𝙑𝘼𝙏𝙄𝙊𝙉 𝙁𝙄𝙉𝘼𝙉𝘾𝙄𝘼𝙇 𝙎𝙐𝙋𝙋𝙊𝙍𝙏 category. Basic Pharma portfolio consists of an IMP department, labservices and a biotech department. The company has grown into a one-stop-shop that can deliver worldwide to the pharmaceutical, biotech and medical device industry. The addition of biotech services, makes Basic Pharma an interesting partner for the development of biologicals. 👉 “𝘛𝘩𝘦 #BioMan4R2 𝘢𝘭𝘭𝘰𝘸𝘦𝘥 𝘢𝘯𝘥 𝘢𝘤𝘤𝘦𝘭𝘦𝘳𝘢𝘵𝘦𝘥 𝘵𝘩𝘦 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘰𝘶𝘳 𝘧𝘪𝘳𝘴𝘵 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘫𝘰𝘪𝘯𝘵 𝘴𝘶𝘱𝘱𝘭𝘺 𝘤𝘩𝘢𝘪𝘯 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘪𝘰𝘯 𝘰𝘧 𝘱𝘳𝘰𝘵𝘦𝘪𝘯𝘴 𝘣𝘦𝘵𝘸𝘦𝘦𝘯 𝗕𝗮𝘀𝗶𝗰 𝗣𝗵𝗮𝗿𝗺𝗮 (𝗡𝗟) 𝘢𝘯𝘥 ARTES Biotechnology GmbH (𝘋𝘌). 𝘐𝘯 𝘵𝘩𝘪𝘴 𝘪𝘯𝘪𝘵𝘪𝘢𝘭 𝘱𝘳𝘰𝘫𝘦𝘤𝘵 𝘢 𝒕𝒚𝒑𝒊𝒄𝒂𝒍 𝒔𝒖𝒑𝒑𝒍𝒚 𝒄𝒉𝒂𝒊𝒏 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕 𝒇𝒐𝒓 𝒃𝒊𝒐𝒍𝒐𝒈𝒊𝒄𝒂𝒍𝒔 (𝒉𝒆𝒓𝒆 𝒉𝒖𝒎𝒂𝒏 𝒔𝒆𝒓𝒖𝒎 𝒂𝒍𝒃𝒖𝒎𝒊𝒏) 𝒘𝒂𝒔 𝒄𝒐𝒗𝒆𝒓𝒆𝒅 𝘴𝘵𝘢𝘳𝘵𝘪𝘯𝘨 𝘧𝘳𝘰𝘮 𝘴𝘵𝘳𝘢𝘪𝘯 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘶𝘯𝘵𝘪𝘭 𝘧𝘪𝘭𝘭&𝘧𝘪𝘯𝘪𝘴𝘩. 𝘍𝘰𝘳 𝘣𝘰𝘵𝘩 𝘤𝘰𝘮𝘱𝘢𝘯𝘪𝘦𝘴 𝘵𝘩𝘪𝘴 𝘷𝘢𝘭𝘪𝘥𝘢𝘵𝘦𝘴 𝘵𝘩𝘦 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺 𝘵𝘰 𝘸𝘰𝘳𝘬 𝘵𝘰𝘸𝘢𝘳𝘥𝘴 𝙖 𝙣𝙚𝙬 𝙫𝙖𝙡𝙪𝙚 𝙘𝙝𝙖𝙞𝙣 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘦𝘧𝘧𝘪𝘤𝘪𝘦𝘯𝘵 𝘤𝘰-𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘯𝘦𝘸 (𝘱𝘩𝘢𝘳𝘮𝘢𝘤𝘦𝘶𝘵𝘪𝘤𝘢𝘭) 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘴. 𝘛𝘩𝘢𝘵 𝘤𝘢𝘯 𝘣𝘦 𝘵𝘳𝘢𝘯𝘴𝘭𝘢𝘵𝘦𝘥 𝘵𝘰 𝘰𝘵𝘩𝘦𝘳 𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘴.” 🎉Congratulations 𝗕𝗮𝘀𝗶𝗰 𝗣𝗵𝗮𝗿𝗺𝗮 on your achievements! 🎉 #resilience #europeanunion #biotech #innovation #medicaldevice #EUfunding #medtech #cascadefunding Turku Science Park Ltd Council of European BioRegions - CEBR Biocat, BioRegion of Catalonia BioRegio STERN Management GmbH MedSilesia Cluster - Silesian Medical Devices Network Górnośląski Akcelerator Przedsiębiorczości Rynkowej sp. z o.o. Medicen Paris Region LifetecZONe

Development of Basic Pharma´s first #European joint #supply chain for the production of proteins together with Artes showcases the great #impact and #resilience gained via the granted #financial support in the framework of #BioMan4R2.

There is solid evidence that innovative treatments have drastically improved our lives. We live longer and we enjoy better quality of life. But.. …do we do enough to protect access to innovative treatments? Have we developed a business environment that is sustainable and predictable? Have we looked at best practices from other EU member states? PhARMA Innovation Forum Greece (PIF) has clearly articulated that more needs to be done. The time to act is now. The time to seek synergies is now. Let’s not waste another opportunity!

Getting ready for our 10th Annual Edition Master Data and Data Governance Excellence in Life Sciences 💥

Reducing time-to-market for #biopharma companies remains a critical driver of program value. How can companies accelerate product development & commercialization without compromising quality? Incorporate a patient-first approach into scientific, target-first conversations, advises BLV partner Andy Seid. See what other insights he has shared with Pharma's Almanac: https://lnkd.in/d-_S-6Qs #venturecapital #pharma #drugdevelopment #drugdelivery #biotech

👉 Clinician wondering who the top innovators in drug development are? Definitely need to check out the PIII from the folks at IDEA Pharma | From R&D to RxD 🧠 Working in drug development exposed me to an entirely new industry that forms a critical part of the overall healthcare ecosystem 💊 Learning how medicines were made (and the challenges within the grueling and expensive development process) was incredibly synergistic with my patient care experience ⚡ I read this every year - you might like it too! ❓ Interested in all of the ways clinical experience could be valuable across the healthcare ecosystem for your career? Check out Next Degree - you might find the role just for you within our 2000+ jobs right now! PS - the folks at IDEA Pharma | From R&D to RxD are wicked smart

The 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞 (𝐎𝐏𝐄𝐗) 𝐢𝐧 𝐏𝐡𝐚𝐫𝐦𝐚 is here! Join us as we reflect on our impactful publications in 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚, where we delve into the evolution of OPEX over the decades. Our insights reveal how industry practices have transformed and propose four strategic pathways to elevate OPEX in the pharmaceutical landscape. As we face ever-changing challenges, embracing innovation in operations has never been more critical. 𝑨𝒖𝒕𝒉𝒐𝒓𝒔: Mark Grothkopp, Lorenzo Pirrone and Thomas Friedli, University of St.Gallen 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐦𝐨𝐫𝐞: https://lnkd.in/gugtxD2x #pharma #operationalexcellence #innovation #opex #leadership #pharmaceuticalindustry #continuousimprovement #futureofwork #analytics #industryinsights #research #optimization #changemanagement #pharmafocusasia #markgrothkopp #lorenzopirrone #thomasfriedli

The 2024 Pharmaceutical Innovation and Invention Index is live! We are proud to publish this year's indices: the 13th year of analysing innovation and invention in our industry. https://lnkd.in/e_b_TtCY The question, 'if you give the same molecule to two companies in phase I, would they be equally successful?' remains a defining one. The answer is clearly 'no,' so the more interesting question is 'why'?'—perhaps one of the most important questions for our industry. When we first asked ourselves that question, more than a decade ago, it followed a more soul-searching one: ‘what if we're wrong?’ A healthy question, but not one that is typical of consultancies. Understanding how companies create value from their pipelines means being open to novel and multiple approaches - we produce this Index so that we know what we’re talking about when we talk about pharmaceutical innovation. If you like, we’re ‘following the science’ rather than assuming we’re right.

📈 In the dynamic and highly competitive pharmaceutical and biotech industry, aligning enterprise strategy with portfolio operations is key to maintaining a competitive advantage. Our latest blog post showcases how we recently helped a client reshape their portfolio and facilitate better decision-making. 🔍Curious why PwC is a trusted partner in Project & Portfolio Management and how our experts can assist you? 👉Check out our insights https://lnkd.in/e_E7m5xQ or reach out to us directly. #HealthIndustry #Pharma #Biotech #ProjectManagement #PortfolioManagement #Innovation #CompetitiveAdvantage #PwCBelgium